Provention Bio, Inc.
PRVB · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $790 | $355 | $889 | $607 |
| - Cash | $44 | $78 | $102 | $39 |
| + Debt | $24 | $1 | $1 | $0 |
| Enterprise Value | $770 | $277 | $787 | $568 |
| Revenue | $13 | $1 | $0 | $0 |
| % Growth | 824.4% | – | – | – |
| Gross Profit | $12 | $1 | $0 | $0 |
| % Margin | 96% | 100% | – | – |
| EBITDA | -$125 | -$115 | -$100 | -$44 |
| % Margin | -967% | -8,257.4% | – | – |
| Net Income | -$114 | -$114 | -$99 | -$42 |
| % Margin | -880.7% | -8,203% | – | – |
| EPS Diluted | -1.52 | -1.81 | -1.88 | -1.04 |
| % Growth | 16% | 3.7% | -80.8% | – |
| Operating Cash Flow | -$75 | -$95 | -$76 | -$36 |
| Capital Expenditures | -$1 | -$1 | -$1 | $0 |
| Free Cash Flow | -$76 | -$96 | -$77 | -$36 |